Instillation therapies
Instillation therapies represent a treatment option in the management of non-muscle invasive bladder cancer (NMIBC). This therapeutic approach involves the direct introduction of the medication into the bladder with the aim of targeting cancer cells residing in the bladder lining while minimizing systemic exposure. Unlike systemic treatments that circulate throughout the body, instillation therapies focus on the local therapeutic effect specifically within the bladder. This targeted approach is particularly beneficial in cases where the cancerous cells have not infiltrated deeper layers of the bladder or spread to distant sites in the body.
Instillation therapies offer the advantage of being administered on an outpatient basis, allowing patients to return home shortly after treatment without the need for extended hospitalization. This not only enhances convenience and comfort for patients, but also contributes to cost-effectiveness within healthcare systems.
Moreover, instillation therapies can be tailored to individual patient needs and disease characteristics, with treatment schedules specifically designed to induce a response and reduce the risk of disease recurrence and progression. Regular monitoring and follow-up assessments are integral components of instillation therapy schedules, enabling healthcare providers to track treatment efficacy, assess for recurrence or progression, and optimize patient outcomes over time.
Intravesical immunotherapy
Intravesical immunotherapy is a treatment method for non-muscle invasive bladder cancer that involves the direct delivery of immunotherapy agents into the bladder. These agents train the immune system by causing a local inflammation. This is intentional and is used therapeutically because it activates the body‘s immune defenses. The induced inflammation enables the immune system to recognize and specifically eliminate remaining tumour cells. This can markedly reduce the risk of bladder cancer recurrence and progression (worsening of the disease).
This treatment is typically administered as an outpatient procedure, with the immunotherapy agents instilled into the bladder through a thin catheter. Patients need to retain the medication in their bladder for a certain period of time (referred to as dwell-time) to allow for optimal absorption and efficacy. Intravesical immunotherapy offers the advantage of localized treatment, minimizing systemic side effects while effectively targeting cancer cells within the bladder. It can be used alone or in combination with other treatments, depending on the individual patient's needs and disease characteristics.
Regular follow-up assessments are crucial to monitor treatment response and detect any signs of cancer recurrence or progression. Overall, intravesical immunotherapy represents a promising approach to managing non-muscle invasive bladder cancer, offering the potential for improved outcomes and quality of life for patients.
LOG IN TO EXPLORE MORE
Learn more about intravesical immunotherapy
Intravesical chemotherapy
Intravesical chemotherapy is a specialized treatment for non-muscle invasive bladder cancer, which involves delivering chemotherapeutic drugs directly into the bladder to kill actively growing cancer cells. Unlike traditional chemotherapy given intravenously, intravesical chemotherapy is targeted specifically at cancer cells in the bladder lining (bladder mucosa and submucosa).
This treatment is typically administered as an outpatient procedure, with the chemotherapy drugs instilled into the bladder through a thin catheter. Patients may need to retain the medication in their bladder for a certain period of time (referred to as the dwell-time) to allow for optimal absorption and efficacy.
Intravesical chemotherapy offers the advantage of localized treatment, effectively targeting cancer cells within the bladder while reducing the risk of side effects on other parts of the body. It can be used as a standalone treatment or in combination with other therapies, depending on the patient's specific condition and treatment plan.
Regular follow-up appointments are essential to monitor the response to treatment and detect any signs of cancer recurrence or progression. Overall, intravesical chemotherapy represents a valuable therapeutic option for managing non-muscle invasive bladder cancer, potentially improving patient outcomes and quality of life.
LOG IN TO EXPLORE MORE
Learn more about intravesical chemotherapy
